Heck Capital Advisors’s ADMA Biologics ADMA Stock Holding History

Heck Capital Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13,123	Closed	-$225K	–	245
2024 Q4	$225K	Buy	+13,123	New	+$247K	0.01%	250

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

Heck Capital Advisors's ADMA Position: Q1 2025 in Review

Heck Capital Advisors sold out of ADMA Biologics (ADMA) in Q1 2025, closing a stake of 13,123 shares — an estimated $225K sold.

Heck Capital Advisors first reported a position in ADMA in Q4 2024 and held it in 1 quarter. The position peaked at $225K in Q4 2024. 347 funds tracked by Wall St. Rank hold ADMA as of Q1 2025.

Heck Capital Advisors reported no remaining ADMA Biologics position as of Q1 2025 after selling out during the quarter.
Heck Capital Advisors sold 13,123 ADMA Biologics shares in Q1 2025, an estimated $225K.
Heck Capital Advisors first reported a position in ADMA Biologics in Q4 2024 and held it in 1 quarter.
Heck Capital Advisors's ADMA Biologics position peaked at $225K in Q4 2024.
347 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2025.

Based on Heck Capital Advisors's 13F filing for Q1 2025, filed 13 May 2025.